RUBIUS THERAPEUTICS INC's ticker is RUBY and the CUSIP is 78116T103. A total of 108 filers reported holding RUBIUS THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $304,000 | -47.3% | 55,123 | -7.4% | 0.00% | -100.0% |
Q4 2021 | $577,000 | -44.1% | 59,560 | +3.1% | 0.00% | 0.0% |
Q3 2021 | $1,033,000 | -31.9% | 57,795 | -7.0% | 0.00% | -50.0% |
Q2 2021 | $1,517,000 | +6.0% | 62,150 | +15.1% | 0.00% | 0.0% |
Q1 2021 | $1,431,000 | +249.0% | 53,993 | 0.0% | 0.00% | +100.0% |
Q4 2020 | $410,000 | +51.3% | 53,993 | 0.0% | 0.00% | – |
Q3 2020 | $271,000 | -16.1% | 53,993 | 0.0% | 0.00% | -100.0% |
Q2 2020 | $323,000 | +34.6% | 53,993 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $240,000 | -52.7% | 53,993 | +1.2% | 0.00% | 0.0% |
Q4 2019 | $507,000 | +20.1% | 53,371 | -0.8% | 0.00% | 0.0% |
Q3 2019 | $422,000 | -50.1% | 53,799 | 0.0% | 0.00% | -50.0% |
Q2 2019 | $846,000 | -11.5% | 53,799 | +1.9% | 0.00% | 0.0% |
Q1 2019 | $956,000 | +205.4% | 52,807 | +170.9% | 0.00% | +100.0% |
Q4 2018 | $313,000 | -29.0% | 19,490 | +6.0% | 0.00% | 0.0% |
Q3 2018 | $441,000 | – | 18,390 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARCH Venture Management, LLC | 2,618,351 | $11,652,000 | 19.67% |
Flagship Pioneering Inc. | 38,296,526 | $170,419,000 | 7.99% |
HARBOURVEST PARTNERS LLC | 986,878 | $4,392,000 | 2.12% |
Abbot Financial Management, Inc. | 563,500 | $2,508,000 | 2.04% |
Artal Group S.A. | 3,883,791 | $17,283,000 | 0.73% |
ARK Investment Management | 318,121 | $1,416,000 | 0.04% |
Walleye Capital LLC | 34,000 | $151,000 | 0.03% |
Tekla Capital Management LLC | 155,982 | $694,000 | 0.03% |
Baillie Gifford | 4,256,900 | $18,943,000 | 0.02% |
FEDERATED HERMES, INC. | 600,000 | $2,670,000 | 0.01% |